New drug ALX2004 targets tough cancers in first human trial

NCT ID NCT07085091

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times

Summary

This early-phase study tests a new drug called ALX2004 in people with advanced or metastatic solid tumors (lung, head and neck, colorectal, or esophageal cancer) that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to cells with a protein called EGFR. The study aims to find a safe dose and check if the drug can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ALX Center 1

    RECRUITING

    Spokane, Washington, 99208, United States

  • ALX Center 2

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • ALX Center 3

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • ALX Center 4

    RECRUITING

    West Valley City, Utah, 84119, United States

  • ALX Center 5

    RECRUITING

    Houston, Texas, 77030, United States

  • ALX Center 6

    RECRUITING

    Portland, Oregon, 97213, United States

  • ALX Center 7

    RECRUITING

    Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.